Latest News

Media: Neurology Live Coverage: FDA Clears IND to Test Intranasal Foralumab in Alzheimer Disease

16 August 2023

FDA Clears IND to Test Intranasal Foralumab in Alzheimer Disease

Aug 15, 2023

Isabella Ciccone, MPH

Foralumab, a therapy designed to bind to T cell receptor, is about to be assessed in phase 2 trials of patients with non-active secondary progressive multiple...

Read more

Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease

15 August 2023

  • Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibody
  • Trial to be overseen by Brigham and Women’s...

Read more

Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice

21 July 2023

New York, July 21, 2023 – Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today disclosed the receipt of a notice (the “Notice”) on...

Read more

Media: Jane King interviews Matthew Davis, M.D., Chief Medical Officer, Tiziana Life Sciences

23 June 2023

Read more

Media: Neurology Live Coverage: Decreased Microglial Activation Observed in Foralumab-Treated Patients With Secondary Progressive MS

15 June 2023

Through an expanded access program, new announced data from a small cohort of patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with foralumab (Tiziana Life Sciences), an investigational anti-CD3 monoclonal antibody, showed reduction in microglial activation after 3 months...

Read more

Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer

13 June 2023

NEW YORK, June 13, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce the appointment of Matthew Davis, MD,...

Read more

Media: MS News Today: Microglial activation reduced in 5 of 6 SPMS patients on nasal foralumab

08 June 2023

Reductions in microglial activation have been observed in the brains of five of six patients with nonactive secondary progressive multiple sclerosis (SPMS) who received treatment with Tiziana Life Science’s foralumab nasal spray.

Microglia, resident immune cells in the brain,...

Read more

Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis

05 June 2023

  • Results confirm positive signal previously reported in the first two Expanded Access patients who both subsequently demonstrated clinical improvements
  • Phase 2a trial in na-SPMS...

Read more

Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS), Webinar to take place on Monday, June 5, 2023 at 12:30 PM ET

25 May 2023

NEW YORK, May 25, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it will host a virtual KOL event...

Read more

Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform

23 May 2023

NEW YORK, May 23, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that they are now participating on the new...

Read more

Page 3 of 30 Previous Next